Is the mineralocorticoid receptor a potential target for stroke prevention?

Jessica M Osmond1, Christine' S Rigsby, Anne M Dorrance

  • 1Department of Physiology, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, USA.

Insights

Mineralocorticoid receptor (MR) antagonism may prevent strokes by protecting cerebral blood vessels. This effect may involve the epidermal growth factor receptor (EGFR) and collagen levels in vessel walls.

Area of Science:

  • Cardiovascular Science
  • Neurology
  • Endocrinology

Background:

  • Aldosterone has significant extra-renal effects contributing to cardiovascular disease pathogenesis.
  • Stroke is a major cause of mortality globally.
  • Mineralocorticoid receptor (MR) antagonism is being investigated as a stroke preventative therapy.

Purpose of the Study:

  • To explore the potential of MR antagonism in preventing both ischaemic and haemorrhagic strokes.
  • To investigate the mechanisms underlying the protective effects of MR antagonism in the cerebral vasculature.

Main Methods:

  • The study focuses on the cerebral vasculature.
  • Investigates the role of epidermal growth factor receptor (EGFR) expression and activation.
  • Examines the impact on vessel wall collagen deposition.

Main Results:

  • MR antagonism demonstrates a protective effect against stroke.
  • This protection is linked to actions within the cerebral vasculature.
  • Potential mechanisms involve EGFR signaling and collagen accumulation.

Conclusions:

  • MR antagonism represents a promising therapeutic strategy for stroke prevention.
  • The protective effects are mediated through the cerebral vasculature.
  • EGFR and collagen deposition are identified as key factors in this protective mechanism.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Regulation of Stroke Volume01:27

Regulation of Stroke Volume

The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...